drugset
drugset / Trial / NCT04670978

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

NCT04670978 ↗

Phase 2 Unknown 96 enrolled Shandong University
NaSingle-groupOpen-labelTreatment

Summary

The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel） and bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian cancer, fallopian tube cancer or peritoneal carcinoma.

Timeline

Start
2021-03-31
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Biosimilar Unknown 10 mg/kg Other
Subject albumin-bound paclitaxe Unknown 260 mg/m2 Other

Indications

No indication recorded.